Abatacept is a recombinant fusion protein that modulates the immune response by selectively inhibiting T-cell activation. It functions as a CTLA-4-Ig fusion protein, which binds to CD80/CD86 on antigen-presenting cells (APCs), thereby preventing the necessary co-stimulatory signal (CD28-CD80/86) for full T-cell activation. Abatacept is often studied in relation to immunological biomarkers—such as T-cell subsets, cytokine profiles, and autoantibodies—which reflect its biological activity and treatment response in autoimmune diseases.
Clinically, abatacept is approved for rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and psoriatic arthritis, where it serves as a second-line or biologic disease-modifying antirheumatic drug (bDMARD). It is particularly useful in those with inadequate response to TNF inhibitors. In research settings, abatacept is used to probe mechanisms of T-cell tolerance, co-stimulatory signaling, and autoimmune pathogenesis. Studies often use it as a tool to investigate biomarker-guided treatment strategies, including prediction of response via baseline levels of autoantibodies (like RF or anti-CCP), T-cell phenotypes, or gene expression signatures. Its immunomodulatory properties also make it a candidate for exploring therapeutic interventions in type 1 diabetes, lupus, and organ transplant rejection.
This product is manufactured in Turkey by Matriks Biotek.
